Trials / Completed
CompletedNCT00073164
Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia
A Study of the Safety and Efficacy of Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the 14-day and 12-week safety and efficacy of Depakote ER used in combination with either olanzapine or risperidone versus antipsychotic monotherapy with olanzapine or risperidone for the treatment of schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Divalproex Sodium Extended-Release Tablets | |
| DRUG | Olanzapine | |
| DRUG | Risperidone |
Timeline
- Start date
- 2003-07-01
- First posted
- 2003-11-18
- Last updated
- 2006-08-04
Locations
35 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00073164. Inclusion in this directory is not an endorsement.